TJ Jia

Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation.

Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The private company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million.

Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients.

Octagon Capital Advisor/ Private Equity (Octagon Capital) is a private equity subsidiary of Octagon Capital Advisors LP founded in 2019 by Ting Jia. The firm is headquartered in New York.

Octagon Capital Advisors LP (Octagon) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Ting Jia in 2019. Octagon provides discretionary investment advisory services to master-feeder, mini-master feeder, and Delaware series trust structures comprised of affiliated pooled investment vehicles.

HHLR Management Pte Ltd. (HHLR) is an alternative investment management firm headquartered in Singapore. The firm is a subsidiary of Hillhouse Capital Group Ltd. in Hong Kong. Formerly known as Hillhouse Capital Management Pte Ltd., HHLR provides investment solutions to institutional investors as well as to non-profit foundations.

BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts.